Previous data showed that an imbalanced Bcl-2 protein level causally determines hematologic malignant progression and accordingly targeting the Bcl-2 protein family has been proven to be successful, in particular, in hematologic malignancies. This evidence concerns the gene BCL2 and hematologic disorder.